<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">Clin Case Rep</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2050-0904</journal-id><journal-id journal-id-type="publisher-id">CCR3</journal-id><journal-title-group><journal-title>Clinical Case Reports</journal-title></journal-title-group><issn pub-type="epub">2050-0904</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5715601</article-id><article-id pub-id-type="doi">10.1002/ccr3.1226</article-id><article-id pub-id-type="publisher-id">CCR31226</article-id><article-categories><subj-group subj-group-type="overline"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Reports</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>PROS1 novel splice‐site variant decreases protein S expression in patients from two families with thrombotic disease </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="left-running-head">J. Menezes <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="ccr31226-cr-0001" contrib-type="author"><name><surname>Menezes</surname><given-names>Juliane</given-names></name><xref ref-type="aff" rid="ccr31226-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ccr31226-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ccr31226-cr-0002" contrib-type="author"><name><surname>Ventura</surname><given-names>Célia</given-names></name><xref ref-type="aff" rid="ccr31226-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ccr31226-cr-0003" contrib-type="author"><name><surname>Costa</surname><given-names>João Matos</given-names></name><xref ref-type="aff" rid="ccr31226-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="ccr31226-cr-0004" contrib-type="author"><name><surname>Parreira</surname><given-names>Elsa</given-names></name><xref ref-type="aff" rid="ccr31226-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="ccr31226-cr-0005" contrib-type="author"><name><surname>Romão</surname><given-names>Luísa</given-names></name><xref ref-type="aff" rid="ccr31226-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ccr31226-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ccr31226-cr-0006" contrib-type="author" corresp="yes"><name><surname>Gonçalves</surname><given-names>João</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9359-8774</contrib-id><address><email>joao.goncalves@insa.min-saude.pt</email></address><xref ref-type="aff" rid="ccr31226-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ccr31226-aff-0005">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="ccr31226-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Human Genetics</named-content>
<institution>Instituto Nacional de Saúde Doutor Ricardo Jorge</institution>
<named-content content-type="city">Lisbon</named-content>
<country country="PT">Portugal</country>
</aff><aff id="ccr31226-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Gene Expression and Regulation Group</named-content>
<named-content content-type="organisation-division">Biosystems &amp; Integrative Sciences Institute (BioISI)</named-content>
<named-content content-type="organisation-division">Faculdade de Ciências</named-content>
<institution>Universidade de Lisboa</institution>
<named-content content-type="city">Lisbon</named-content>
<country country="PT">Portugal</country>
</aff><aff id="ccr31226-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Third Department of Internal Medicine</named-content>
<institution>Hospital Distrital de Santarém</institution>
<named-content content-type="city">Santarém</named-content>
<country country="PT">Portugal</country>
</aff><aff id="ccr31226-aff-0004">
<label><sup>4</sup></label>
<institution>Hospital Fernando Fonseca</institution>
<named-content content-type="city">Amadora</named-content>
<country country="PT">Portugal</country>
</aff><aff id="ccr31226-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Centre for Toxicogenomics and Human Health (ToxOmics)</named-content>
<named-content content-type="organisation-division">Genetics, Oncology and Human Toxicology</named-content>
<named-content content-type="organisation-division">Nova Medical School</named-content>
<institution>Universidade Nova de Lisboa</institution>
<named-content content-type="city">Lisbon</named-content>
<country country="PT">Portugal</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
João Gonçalves, Department of Human Genetics, Instituto Nacional de Saúde Doutor Ricardo Jorge, Av. Padre Cruz s/n, 1649‐016, Lisboa, Portugal. Tel: (+351) 217519320; Fax: (+351) 217526400; E‐mail: <email>joao.goncalves@insa.min-saude.pt</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2017</year></pub-date><volume>5</volume><issue>12</issue><issue-id pub-id-type="doi">10.1002/ccr3.2017.5.issue-12</issue-id><fpage>2062</fpage><lpage>2065</lpage><history><date date-type="received"><day>08</day><month>6</month><year>2017</year></date><date date-type="rev-recd"><day>04</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>19</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement content-type="article-copyright">© 2017 The Authors. <italic>Clinical Case Reports</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CCR3-5-2062.pdf"/><abstract id="ccr31226-abs-0001"><title><text><SENT sid="1" pm="."><plain>Key Clinical Message </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Our results prove that c.1871‐14T&gt;G is causative of type I PS deficiency, highlighting the importance of performing mRNA‐based studies in order to evaluate variants pathogenicity. </plain></SENT>
<SENT sid="3" pm="."><plain>We evidence the increased risk of venous thromboembolism associated with this cryptic splice‐site variant if present in patients with PS deficiency. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group kwd-group-type="author-generated"><kwd id="ccr31226-kwd-0001"><italic><styled-content style="fixed-case">PROS</styled-content>1</italic></kwd><kwd id="ccr31226-kwd-0002">protein S deficiency</kwd><kwd id="ccr31226-kwd-0003">thrombophilia</kwd><kwd id="ccr31226-kwd-0004">thrombosis</kwd><kwd id="ccr31226-kwd-0005">venous thromboembolism</kwd></kwd-group></SecTag><funding-group><award-group><funding-source>Fundação para a Ciência e a Tecnologia</funding-source><award-id>SFRH/BPD/98360/2013</award-id><award-id>UID/BIM/00009/2013</award-id></award-group><award-group><funding-source>Centre for Toxicogenomics and Human Health—ToxOmics</funding-source></award-group><award-group><funding-source>Genetics, Oncology and Human Toxicology</funding-source><award-id>UID/BIM/00009/2013</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="0"/><page-count count="4"/><word-count count="2023"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>ccr31226</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.7 mode:remove_FC converted:05.12.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ccr31226-cit-1001">
<source>Clinical Case Reports</source>
<year>2017</year>; <volume>5</volume>(<issue>12</issue>): <fpage>2062</fpage>–<lpage>2065</lpage>
</mixed-citation>
</p></notes></front><body><SecTag type="INTRO"><sec id="ccr31226-sec-0001"><title><text><SENT sid="4" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="5" pm="."><plain>Protein S (PS) is a widely studied protein with an important function in the downregulation of thrombin formation. </plain></SENT>
<SENT sid="6" pm="."><plain>Since its discovery in 1976, more than 400 variants have been described in PS gene (PROS1) associated with PS deficiency and as a risk factor for venous thromboembolism (VTE). </plain></SENT>
<SENT sid="7" pm="."><plain>We describe a novel variant, c.1871‐14T&gt;G, in intron 14 of PROS1 gene identified in two patients with PS deficiency from two unrelated families with a history of thrombotic disease. </plain></SENT>
<SENT sid="8" pm="."><plain>This alteration leads to a PROS1 mRNA expression reduction, probably due to nonsense‐mediated mRNA decay. </plain></SENT>
<SENT sid="9" pm="."><plain>Our results suggest that c.1871‐14T&gt;G is causative of type I PS deficiency in these patients, highlighting the importance of screening not only the coding and the most conserved intron–exon junctions, but also perform mRNA‐based studies. </plain></SENT>
<SENT sid="10" pm="."><plain>We call attention to the potential increased risk of VTE in hereditary type I PS deficiency associated with this cryptic splice‐site variant. </plain></SENT>
</text></p></sec></SecTag><sec id="ccr31226-sec-0002"><title><text><SENT sid="11" pm="."><plain>Report </plain></SENT>
</text></title><p><text><SENT sid="12" pm="."><plain>Hereditary PS deficiency (PSD) is an autosomal dominant disorder associated with an increased risk of venous thromboembolism (VTE) 1, 2. </plain></SENT>
<SENT sid="13" pm="."><plain>The genetic basis of PSD is heterogeneous and is also associated with phenotypic variability. </plain></SENT>
<SENT sid="14" pm="."><plain>More than 400 variants in PROS1 have been described, the vast majority being missense or nonsense variants, distributed along the coding region 3. </plain></SENT>
<SENT sid="15" pm="."><plain>In this report, we describe a novel c.1871‐14T&gt;G variant in PROS1 intron 14, identified in two patients from two unrelated families, both with PSD and history of thrombotic disease. </plain></SENT>
</text></p><p><text><SENT sid="16" pm="."><plain>Two unrelated Portuguese women were referred for genetic analysis of the PROS1 gene due to PSD and clinical conditions associated with thromboembolism (Fig. 1A, probands F1‐III2 and F2‐IV3). </plain></SENT>
<SENT sid="17" pm="."><plain>Plasma levels of total (TPS) and free protein S (FPS) antigen were below the lower limit of reference, suggesting type I PSD. </plain></SENT>
<SENT sid="18" pm="."><plain>After obtained informed consent, peripheral blood (PB) samples were collected for PROS1 molecular analysis of patients F1‐III2 and F2‐IV3. </plain></SENT>
<SENT sid="19" pm="."><plain>PB was also available from patient F1‐III2 for mRNA studies, and from her mother and sister for PROS1, c.20210G&gt;A Prothrombin and Factor V Leiden genetic testing. </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="ccr31226-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="20" pm="."><plain>(A) Pedigrees from probands F1‐III2 and F2‐IV3. </plain></SENT>
<SENT sid="21" pm="."><plain>The arrow indicates each proband. </plain></SENT>
<SENT sid="22" pm="."><plain>Relevant results are below each family member: FPS, TPS, FcPS—free, total, and functional protein S, respectively. CVT, cerebral venous thrombosis; AMI, acute myocardial infarction. *Clinical diagnosis and laboratory analysis performed elsewhere. </plain></SENT>
<SENT sid="23" pm="."><plain>Orange and blue—stand for PS deficiency and FV Leiden heterozygosity, respectively. </plain></SENT>
<SENT sid="24" pm="."><plain>Heterozygosity (hetz) for PROS1 variant c.1871‐14T&gt;G and the clinical condition are shadowed in gray. </plain></SENT>
<SENT sid="25" pm="."><plain>(B) DNA sequence results of PROS1 intron 14–exon 15 junctions of F1‐III2, F1‐II4, and F2‐IV3. </plain></SENT>
<SENT sid="26" pm="."><plain>Molecular analysis revealed that F1‐III2 and F2‐IV3 are heterozygous for PROS1: c.1871‐14T&gt;G variant (NCBI sequence reference: NM_000313.3) that is predicted to activate new intronic cryptic acceptor splice site. </plain></SENT>
<SENT sid="27" pm="."><plain>(C) PROS1 transcript amplification analysis of exon 14–exon 15 junctions in a 2% agarose gel. </plain></SENT>
<SENT sid="28" pm="."><plain>The 150‐bp fragment in the control (C) and F1‐III2 results from the amplification of the wild‐type (wt) allele, and the 163‐bp fragment found in F1‐III2 is from amplification of the mutant allele. </plain></SENT>
<SENT sid="29" pm="."><plain>The 70‐bp fragment in the C and F1‐III2 corresponds to GAPDH (internal control) amplification. </plain></SENT>
<SENT sid="30" pm="."><plain>M: NZYDNA ladder VI; B: Mock. </plain></SENT>
<SENT sid="31" pm="."><plain>(D) Chromatogram of the 163‐bp RT‐PCR fragment from patient F1‐III2. </plain></SENT>
<SENT sid="32" pm="."><plain>The sequence analysis revealed that c.1871‐14T&gt;G variant resulted in the retention of the last 13 nucleotides from intron 14, inserted between exons 14 and 15 in PROS1 mRNA. </plain></SENT>
<SENT sid="33" pm="."><plain>(E) Quantification of wt PROS1 mRNA expression by real‐time PCR from patient F1‐III2. </plain></SENT>
<SENT sid="34" pm="."><plain>The expression levels of PROS1 mRNA were normalized to the internal control GAPDH mRNA. </plain></SENT>
<SENT sid="35" pm="."><plain>The values of PROS1 mRNA amplicons from F1‐III2 were compared to the control sample, arbitrarily set to 1. </plain></SENT>
<SENT sid="36" pm="."><plain>Patient F1‐III2 produces 40% of total wt PROS1 mRNA when compared to a healthy control (P = 0.035). </plain></SENT>
<SENT sid="37" pm="."><plain>(F) In silico prediction of c.1871‐14G&gt;T variant in the PROS1 protein sequence. </plain></SENT>
<SENT sid="38" pm="."><plain>The insertion in the mutant allele alters the reading frame and predicting a truncated protein that loses all amino acids encoded by exon 15 and gains a premature stop codon. </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-3" xlink:href="CCR3-5-2062-g001"/></fig><p><text><SENT sid="39" pm="."><plain>As there were no other factors that could potentially result in a decrease in PS levels in patients F1‐III2 and F2‐IV3, hereditary type I PSD was suspected (Fig. 1A). </plain></SENT>
<SENT sid="40" pm="."><plain>Standard molecular analysis of PROS1 4 culminated with the identification of a T&gt;G transversion at position‐14 of the acceptor splice site of intron 14 in patients F1‐III2 and F2‐IV3. </plain></SENT>
<SENT sid="41" pm="."><plain>This alteration was not identified in the mother of F1‐III2 (Fig. 1B), suggesting that it is of paternal origin. </plain></SENT>
<SENT sid="42" pm="."><plain>To our knowledge, the PROS1 c.1871‐14T&gt;G variant was not described associated with PSD and it is very rare in the general population (rs754929347; MAF C = 0.000009/1). </plain></SENT>
<SENT sid="43" pm="."><plain>Analysis of this variant using the Alamut‐v2.2 interactive biosoftware predicted the creation of a new cryptic acceptor splice site (scores: SSF = 71.78; MaxEnt = 2.32 and HSF = 76.10). </plain></SENT>
</text></p><p><text><SENT sid="44" pm="."><plain>As c.1871‐14T&gt;G has a potential effect on intron 14–exon 15 acceptor splice site, we decided to study its PROS1 mRNA. </plain></SENT>
<SENT sid="45" pm="."><plain>For this purpose, RNA was isolated from fresh PB leukocytes (obtained from patient F1‐III2) and cDNA was amplified. </plain></SENT>
<SENT sid="46" pm="."><plain>As a result, two PCR products of 150‐bp and 163‐bp in the patient cDNA were amplified, unlike the healthy control sample in which only the wild‐type (wt) allele of 150‐bp was obtained, as expected (Fig. 1C). </plain></SENT>
<SENT sid="47" pm="."><plain>To better characterize the 150‐bp and 163‐bp fragments, both were separately cloned and sequenced. </plain></SENT>
<SENT sid="48" pm="."><plain>We found, as expected, that the 150‐bp fragment from the patient and the control sample corresponds to the wt allele with the correct junction of exons 14 and 15 (data not shown). </plain></SENT>
<SENT sid="49" pm="."><plain>However, the 163‐bp fragment retained the last 13 nucleotides (nt) of intron 14 (Fig. 1D). </plain></SENT>
<SENT sid="50" pm="."><plain>In order to quantitatively evaluate the expression level of wt PROS1 mRNA in proband F1‐III2, we performed real‐time PCR using specific primers for the wt allele (Fig. 1E). </plain></SENT>
<SENT sid="51" pm="."><plain>Our results demonstrated that the patient F1‐III2 sample has only 40% of total wt PROS1 mRNA when compared to the healthy control (P = 0.035). </plain></SENT>
</text></p><p><text><SENT sid="52" pm="."><plain>Finally, we decided to investigate how the retention of these 13 nt in the mRNA of PROS1 would affect the PROS1 protein. </plain></SENT>
<SENT sid="53" pm="."><plain>In silico analysis using the ExPASy translate tool revealed that the additional 13 nt of the mutant allele, alters the reading frame, predicting a truncated protein that loses all amino acids encoded by exon 15 (green sequence) and creates a premature termination codon (PTC) 17 amino acids downstream (red sequence) (Fig. 1F). </plain></SENT>
<SENT sid="54" pm="."><plain>However, nonsense‐mediated mRNA decay (NMD) may recognize and selectively degrades this mRNA carrying PTC, preventing the production of a truncated protein. </plain></SENT>
</text></p><p><text><SENT sid="55" pm="."><plain>To date, only few studies have experimentally demonstrated the functional consequences of PROS1 variants associated with type I PSD. </plain></SENT>
<SENT sid="56" pm="."><plain>Variants in PROS1 leading to deleterious alleles, such as frameshift or splice‐site variants, result in significant sequence alterations and often introduce PTCs, as was demonstrated with this study. </plain></SENT>
<SENT sid="57" pm="."><plain>In addition, in silico splice‐site prediction tools are not enough to take definitive conclusions about the variants functional consequences. </plain></SENT>
<SENT sid="58" pm="."><plain>Additional mRNA‐based studies should be performed when putative splicing variants are identified. </plain></SENT>
<SENT sid="59" pm="."><plain>To elucidate the genetic causes underlying PSD and the heterogeneity observed in its phenotypic manifestation, it is essential to investigate the consequences of naturally occurring PROS1 variants. </plain></SENT>
<SENT sid="60" pm="."><plain>Our results shed some light on the mechanism by which splice‐site variants can alter plasma PS levels. </plain></SENT>
</text></p><p><text><SENT sid="61" pm="."><plain>Concerning the risk of VTE, both patients have PS levels below the lower limit of the reference range. </plain></SENT>
<SENT sid="62" pm="."><plain>This splicing variant probably results in a reduced synthesis of PS reflected in lower levels of FPS and TPS identified in the affected members of these two families, and possibly they have a putative increased risk of VTE as was reported in previous studies 2, 5. </plain></SENT>
<SENT sid="63" pm="."><plain>We also emphasize the occurrence of a thrombotic episode at an early age (26 years) in patient F1‐III1, which probably is related to the cumulative effect of the cosegregation of PROS1: c.1871‐14T&gt;G and FV Leiden, another well‐known risk factor for thrombosis, demonstrating that the risk of thrombosis is higher in carriers of double defects. </plain></SENT>
</text></p><p><text><SENT sid="64" pm="."><plain>In conclusion, we describe a novel c.1871‐14T&gt;G splice‐site variant probably causative of type I PSD and supports the importance of the molecular and functional characterization of naturally occurring PROS1 variants, such as mRNA‐based studies in the cases of putative splice‐site variants. </plain></SENT>
</text></p></sec><sec id="ccr31226-sec-0004"><title><text><SENT sid="65" pm="."><plain>Authorship </plain></SENT>
</text></title><p><text><SENT sid="66" pm="."><plain>JM: designed and performed the mRNA experiments, analyzed the results, and wrote the manuscript. </plain></SENT>
<SENT sid="67" pm="."><plain>CV: performed the molecular screening of PROS1 gene and revised the manuscript. </plain></SENT>
<SENT sid="68" pm="."><plain>JMC and EP: established the clinical diagnosis of the index cases of family 1 and 2, respectively. </plain></SENT>
<SENT sid="69" pm="."><plain>LR: analyzed the results and revised the manuscript. </plain></SENT>
<SENT sid="70" pm="."><plain>JG: directed the molecular screening of PROS1, supervised the project, analyzed the results, and revised the manuscript. </plain></SENT>
</text></p></sec><SecTag type="COMP_INT"><sec id="ccr31226-sec-0005"><title><text><SENT sid="71" pm="."><plain>Conflict of Interests </plain></SENT>
</text></title><p><text><SENT sid="72" pm="."><plain>The authors state that they have no conflict of interests. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack id="ccr31226-sec-0003"><title>Acknowledgments</title><p><text4fund><text><SENT sid="73" pm="."><plain>We thank Elizabeth Silva for technical support on total mRNA extraction, Rita Certã for molecular analysis, Isabel Moreira for F2 and factor V Leiden genotyping and to our colleagues of Unidade de Tecnologia e Inovação for technical support with capillary electrophoresis. </plain></SENT>
<SENT sid="74" pm="."><plain>Juliane Menezes is supported by a fellowship from Fundação para a Ciência e a Tecnologia (SFRH/BPD/98360/2013), and this work was partially funded by the Centre for Toxicogenomics and Human Health—ToxOmics, Genetics, Oncology and Human Toxicology from Fundação para a Ciência e a Tecnologia (UID/BIM/00009/2013). </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list content-type="cited-references" id="ccr31226-bibl-0001"><title>References</title><ref id="ccr31226-bib-0001"><text><SENT sid="75" pm="."><plain>1  Gandrille, S. ,  D. Borgel ,  N. Sala ,  Y. Espinosa‐Parrilla ,  R. Simmonds ,  S. Rezende , et al. 2000 Protein S deficiency: a database of mutations–summary of the first update. Thromb. </plain></SENT>
<SENT sid="76" pm="."><plain>Haemost. 84:918.11127877 </plain></SENT>
</text></ref><ref id="ccr31226-bib-0002"><text><SENT sid="77" pm="."><plain>2  Alhenc‐Gelas, M. ,  G. Plu‐Bureau ,  M. </plain></SENT>
<SENT sid="78" pm="."><plain>H. Horellou ,  A. Rauch ,  P. Suchon , and GEHT genetic thrombophilia group . 2016 PROS1 genotype phenotype relationships in a large cohort of adults with suspicion of inherited quantitative protein S deficiency. Thromb. </plain></SENT>
<SENT sid="79" pm="."><plain>Haemost. 115:570–579.26466767 </plain></SENT>
</text></ref><ref id="ccr31226-bib-0003"><text><SENT sid="80" pm="."><plain>3  Stenson, P. </plain></SENT>
<SENT sid="81" pm="."><plain>D. ,  M. Mort ,  E. </plain></SENT>
<SENT sid="82" pm="."><plain>V. Ball ,  K. Evans ,  M. Hayden ,  S. Heywood , et al. 2017 The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next‐generation sequencing studies. Hum. </plain></SENT>
<SENT sid="83" pm="."><plain>Genet. 136:665–677.28349240 </plain></SENT>
</text></ref><ref id="ccr31226-bib-0004"><text><SENT sid="84" pm="."><plain>4  Bustorff, T. </plain></SENT>
<SENT sid="85" pm="."><plain>C. ,  I. Freire ,  T. Gago ,  F. Crespo , and  D. David . 1997 Identification of three novel mutations in hereditary protein S deficiency. Thromb. </plain></SENT>
<SENT sid="86" pm="."><plain>Haemost. 77:21–25.9031443 </plain></SENT>
</text></ref><ref id="ccr31226-bib-0005"><text><SENT sid="87" pm="."><plain>5  Pintao, M. </plain></SENT>
<SENT sid="88" pm="."><plain>C. ,  D. </plain></SENT>
<SENT sid="89" pm="."><plain>D. Ribeiro ,  I. </plain></SENT>
<SENT sid="90" pm="."><plain>D. Bezemer ,  A. </plain></SENT>
<SENT sid="91" pm="."><plain>A. Garcia ,  M. </plain></SENT>
<SENT sid="92" pm="."><plain>C. de Visser ,  C. </plain></SENT>
<SENT sid="93" pm="."><plain>J. Doggen , et al. 2013 Protein S levels and the risk of venous thrombosis: results from the MEGA case‐control study. Blood 122:3210–3219.24014240 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
